Search

PDF file - 403K, Supplemental Figure 1. Heat map of 203 metabolites in 21 pairs of CAFs and NFs. Supplemental Figure 2. The distributions of "relative" t-scores for the 203 metabolites categorized into 46 biochemical subgroupings. Supplemental Figure 3. Total LAMP 2A expression in 8 NF/CAF pairs determined by quantitative Western blotting. Supplemental Figure 4: Alteration in glucose concentration has no consistent effect on NF or CAF growth. Supplemental Figure 5. pH calibration curve constructed for rhodamine-fluorescein (R/F)dextran labeled lysosomes in human fibroblasts. Supplemental Figure 6 (A,B,C,D) Rhodamine-fluorescein (R/F) ratios in arbitrary fluorescent units histograms of ROIs of 4 example CAF/NF pairs.

XLSX file - 1691K, Supplemental Table of metabolomic data

Insulin controls glucose uptake into adipose and muscle cells by regulating the amount of GLUT4 in the plasma membrane. The effect of insulin is to promote the translocation of intracellular GLUT4 to the plasma membrane. The small Rab GTPase, Rab10, is required for insulin-stimulated GLUT4 translocation in cultured 3T3-L1 adipocytes. Here we demonstrate that both insulin-stimulated glucose uptake and GLUT4 translocation to the plasma membrane are reduced by about half in adipocytes from adipose-specific Rab10 knockout (KO) mice. These data demonstrate that the full effect of insulin on adipose glucose uptake is the integrated effect of Rab10-dependent and Rab10-independent pathways, establishing a divergence in insulin signal transduction to the regulation of GLUT4 trafficking. In adipose-specific Rab10 KO female mice, the partial inhibition of stimulated glucose uptake in adipocytes induces insulin resistance independent of diet challenge. During euglycemic-hyperinsulinemic clamp, there is no suppression of hepatic glucose production despite normal insulin suppression of plasma free fatty acids. The impact of incomplete disruption of stimulated adipocyte GLUT4 translocation on whole-body glucose homeostasis is driven by a near complete failure of insulin to suppress hepatic glucose production rather than a significant inhibition in muscle glucose uptake. These data underscore the physiological significance of the precise control of insulin-regulated trafficking in adipocytes.

Cancer cells undergo a metabolic reprogramming but little is known about metabolic alterations of other cells within tumors. We use mass spectrometry–based profiling and a metabolic pathway–based systems analysis to compare 21 primary human lung cancer–associated fibroblast lines (CAF) to “normal” fibroblast lines (NF) generated from adjacent nonneoplastic lung tissue. CAFs are protumorigenic, although the mechanisms by which CAFs support tumors have not been elucidated. We have identified several pathways whose metabolite abundance globally distinguished CAFs from NFs, suggesting that metabolic alterations are not limited to cancer cells. In addition, we found metabolic differences between CAFs from high and low glycolytic tumors that might reflect distinct roles of CAFs related to the tumor's glycolytic capacity. One such change was an increase of dipeptides in CAFs. Dipeptides primarily arise from the breakdown of proteins. We found in CAFs an increase in basal macroautophagy which likely accounts for the increase in dipeptides. Furthermore, we show a difference between CAFs and NFs in the induction of autophagy promoted by reduced glucose. In sum, our data suggest that increased autophagy may account for metabolic differences between CAFs and NFs and may play additional as yet undetermined roles in lung cancer. Mol Cancer Res; 11(6); 579–92. ©2013 AACR.

harbored Kinesin Family Member 5B ALK (KIF5B-ALK) fusion, 4 samples harbored huntingtin interacting protein 1 ALK (HIP1-ALK) fusion, 1 sample harbored kinesin light chain 1 ALK (KLC1-ALK) fusion, and the remaining 16 samples harbored novel fusion variants. Of the 133 EML4-ALK positive samples, 55 samples harbored E13:A20 variants (Variant 1), 55 samples harbored E6:A20 (Variant 3), 16 samples harbored E20:A20 (Variant 2), 4 samples harbored E18:A20 and 3 samples harbored E2:A20. Conclusion: This is the largest molecular epidemiological study to describe ALK fusion variants in East Asian LUAC patients. EML4 is the most common fusion partner of ALK gene. About 84% of ALK fusion positive patients harbor EML4-ALK, and 5.7% harbor nonEML4-ALK fusions. The remaining 10% harbor fusions with unknown partners. For EML4-ALK, E13:A20 and E6:A20 are the most common variants, comprising more than 80% of EML4-ALK fusion. E20:A20, E18:A20 and E2:A20 are also identified in East Asian patients. The constitution of EML4-ALK fusion variants is similar to the previous reports of patient cohorts in western countries. All the ALK fusion variants mentioned should be included in the LUAC fusion screening assays.